---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-121738"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:12:19.751311+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics extends Adcirca license with Lilly through Dec 2026

## Summary
- Exclusive US marketing license for Adcirca extended from Dec 31, 2023 to Dec 31, 2026.
- Other terms of the license agreement remain unchanged.
- Adcirca (tadalafil) is for treatment of pulmonary hypertension in the US.

## SEC filing metadata
- accession: 0001104659-23-121738
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465923121738/0001104659-23-121738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465923121738/tm2323177d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-121738
- JSON: https://secwatch.observer/filing/0001104659-23-121738.json
- Plain text: https://secwatch.observer/filing/0001104659-23-121738.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.